Science and Technology Park
NDI Foundation posted this:Strain of bacteriorhodopsin-BRBacteriorhodopsin (BR) is the newest biotechnological product that will make a revolution in many spheres of life: from medicine to defense. Data on the production of the BR in the world is hidden. From open sources - the only seller (and, possibly, producer) is an American company SIGMA, selling BR for research. We offer developed strain of BR. A method of producing allows to get BR in large quantities to several kg. The strain is certified and stored in special depositories. BR has unique qualities - the main one is - memory. For BR, it was necessary to find a special strain - producer of BR. Just several countries has the strain (USA, Russia, ..), other data hidden. We also developed such an unique strain.
RAMOT at Tel Aviv University Ltd. posted this:A novel behavioral bioassay for preclinical testing and characterization of CNS agentsOur team, including zoologists, statisticians, and computer scientists have developed a new hi-res bioassay for preclinical testing and characterization of CNS agents, extracting key animal-centered parameters of behavior via computerized tracking and measurement of free exploration. The features that distinguish our system and method from other existing systems and methods are: elaborate data preparation for analysis and a methodology that secures replicability of results across laboratories, and exposes active management of kinematic variables. Our measured parameters are carefully designed, animal-centered building blocks of behavior. They are selected on the basis of an in-depth understanding of the mouse’s functional world. These quite unexpected and unusual parameters reflect the animal’s cognitive and emotional state and its information processing capacity; therefore they are most prone to be affected by drugs that act on respective CNS structures that mediate these states. Unlike all other existing systems we expose and quantify the rich and highly organized developmental dynamics of self regulated behavioral growth. The dynamics of this process before and after genetic manipulation and/or pharmacological treatment can now be readily measured by our system, articulating the effects of potential CNS drugs on behavioral growth and decay processes. Project ID : 2-2009-11
RAMOT at Tel Aviv University Ltd. posted this:Oral Mucosa-derived Stem Cells: A Unique Population for the Prevention and Treatment of Ischemic Heart FailureStem cells (SC) are considered crucial building blocks for any regenerative strategy. Adult oral mucosa (OM) is a unique source for generating adult pluripotent stem cell (OPSC) populations. This uniqueness consists in the fact that 95% of the OM whole populations in culture (1st – 8th passages) express markers of embryonic and mesenchymal SC. Thus, in contradistinction to known sources which comprise very low numbers of SC, OPSC generation for clinical use is simple and cost effective and does not require cumbersome cost-consuming purification steps. The general objective is to lay the foundation for the development of a variety of products based on the pluripotency and simple and cost effective generation of billions of OPSC. The major aim of the proposed project is to develop a product for the treatment of ischemic heart failure (IHF). This product which will serve as a proof of concept was selected based on medicals needs, market cap and time to market. The specific aims of the proposal are: 1. To develop a cardiac product aimed at treating ischemic heart failure (IHF). The aim is to test the safety and therapeutic effect of OPSC on experimental IHF in a minipig model. 2. To strengthen the intellectual property by fully characterizing the profile of OPSC. The prevalence of IHF continuously increases (1 million new cases every year in the western world) and currently the market cap is estimated in the range of billions. Project ID : 10-2011-260
RAMOT at Tel Aviv University Ltd. posted this:Immunotherapy for Stroke and Cognition in a Cerebral Amyloid Angiopathy Animal ModelCerebral amyloid angiopathy (CAA) is due to amyloid accumulation in the vessel walls leading to hemorrhagic stroke, and cognitive impairment. There are no available treatments to specifically reduce the risk of CAA. In this research we aim to assess brain tissue damage and cognitive impairment resulting from CAA in animal model and to investigate a novel approach to immune therapy. Methods: We have shown that nasal vaccination with a proteosome adjuvant (Protollin) that is well tolerated in humans, decreases amyloid plaques in an Alzheimer’s disease mouse model. It was recently reported that an overexpression of TGF-?1 under the control of an astrocyte promoter GFAP in mice results in CAA. TGF-?1 mice were nasally treated with Protollin on a weekly basis starting at the age of 13 months for three months. Following treatment animals were subjected for MRI and cognition analysis. Results: Here we show that nasal Protollin activates perivascular macrophage and potently decreases vascular amyloid in TGF-?1 mice. Using MRI we found that while PBS treated animals showed a significant enlargement of the lateral ventricles area, Protollin prevents further brain damage and prevents pathological changes in the blood-brain barrier. Vascular risk factors have been found to be associated with vascular dementia. Using an object recognition test and Y-maze, we found significant improvement in cognition with the Protollin treated group. Interpretation :Our study demonstrates that activation of macrophages by Protollin is a novel approach to reduce microhemorrhage, prevent stroke and improve cognition in a model of cerebral amyloid angiopathy. Project ID : 10-2011-259
Fundació URV posted this:A robust breast cancer computer-aided diagnosis systemWe analyze breast cancer in mammographies, ultrasonographies, magnetic resonance imaging (MRI) and thermographies. Our analysis includes mass/normal breast tissue classification, benign/malignant tumor classification in mammograms and ultrasound images, tumor detection in thermograms, mammogram registration and analysis of the evolution of breast tumors. We also quantify and visualize the evolution of breast tumors in patients undergoing medical treatment. While the previous works mainly focus on analyzing one type of breast images, we implement a robust CAD system for detecting, classifying and studying the evolution of breast cancer. This CAD system analyzes breast cancer in several types of medical images. To implement our CAD system, we use computer vision, pattern recognition and machine learning methods. We also need to collect a large scale breast cancer dataset from hospitals. This dataset should include mammograms, ultrasound, thermograms and MRI images for the same patients. Our CAD gives accurate diagnosis results because it gathers information from different sources.
Barcelona Skin Genomic posted this:Recommendation of optimal combinations of natural active compounds to treat disease using a databaseBarcelona Skin Genomic (BSG) is developing a database that compiles information about the effects of different natural active compounds or plant extracts (more than 2500) on gene expression, on the levels of expression of interleukins and other molecules (more than 3400) and on treatment of different diseases (677). This database collects information from more than 5000 scientific articles, integrated by biologists and experts in life sciences and is updated on a monthly basis.
Creative Biogene posted this:Human SSTR1-FLAG Stable Cell Line-CHOSomatostatin receptors (SSTRs) are activated by somatostatin secreted from nerve and endocrine cells. SSTRs are expressed in a tissue-specific manner and involved in the regulation of secretion of insulin, glucagon and growth hormone as well as cell growth induced by neuronal excitation in both the central and peripheral nervous systems.
Creative Biogene posted this:Human HTR6-FLAG Stable Cell Line-CHOHuman 5-HT6 receptors are G protein-coupled receptors. The cDNA encodes a 440-amino-acid polypeptide. The 5-HT6 receptors are expressed exclusively in brain regions such as striatum, cortex, nucleus accumbens, olfactory tubercle, hippocampus, hypothalamus, amygdala and cerebellum.
RAMOT at Tel Aviv University Ltd. posted this:Novel Anti Bacterial DrugTwo non-toxic short peptides were conjugated to form a novel drug candidate. One of the peptides is a polymyxin-B or polymyxin-E analog (PMBN or PMEN, respectively) while the other is an immune cell chemotactic peptide (fMLF). The resultant new drug candidates (PMBN-fMLF or PMEN-fMLF) exhibit three antimicrobial activities: (a) it binds specifically to gram negative bacteria, thus enhancing penetration of antibiotics into the bacteria and (b) it promotes bacterial killing by blood phagocytes and (c) It binds to free LPS in the blood thus reduces effect on patients. Project ID : 10-2007-98
RAMOT at Tel Aviv University Ltd. posted this:GSK-3 Peptide Inhibitors for the Treatment of CNS Related DisordersNovel Glycogen synthase kinase 3 (GSK-3) inhibitors were developed. These inhibitors are substrate competitors that interact specifically with the GSK-3 substrate binding site. GSK-3, like other protein kinases, has a common structurally conserved catalytic domain that comprises the ATP-binding loop. The great majority of reported inhibitors developed to date are ATP-competitive compounds; however, such inhibitors demonstrate limited specificity, as the ATP-binding pocket is highly conserved among protein kinases. In contrast, the substrate binding site is more specific, and thus targeting inhibitors toward this domain yields more specific compounds. The strategy is based on exploiting the unique recognition motif of GSK-3 which comprises a phosphorylated residue and using molecular and computational analyses. Project ID : 10-2011-132
RAMOT at Tel Aviv University Ltd. posted this:Improved Calcitonin-based TherapeuticsThe aggregation site on human calcitonin has been identified, paving the way for development of specific inhibitors of calcitonin amyloid fibril formation. Such inhibitors will enable development of improved calcitonin therapeutics as well as greatly facilitate in vitro calcitonin manipulations. Project ID : 10-2007-103
RAMOT at Tel Aviv University Ltd. posted this:Novel markers for the identification and isolation of stem and progenitor cellsA series of novel markers: (1) chromatin remodeling protein factor termed (CHD9/CReMM), (2) A cell adhesion protein termed (SVEP1), (3) A kinesin protein termed (MS-KIF18A), (4) RNA processing factor (SRRF/hNRNP-L) have been developed as novel markers for the identification and isolation of stem and progenitor cells. Project ID : 10-2007-104